Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

SHY trades at $81.175, up 0.02% on the day, amid a bearish technical signal driven by moving averages. The stock shows neutral oscillators but faces selling pressure from the ADX indicator. Recent corporate actions include dividends scheduled for late 2026, with payouts of $0.24-$0.25 per share. The broader bond market context, with rising yields, influences sentiment around short-term bond ETFs like SHY.

The outlook for SHY is cautious due to technical bearishness and macroeconomic headwinds from rising interest rates. Opportunities exist for income-focused investors via dividends, but risks include prolonged bond market volatility and Fed policy uncertainty. Investor sentiment remains mixed, balancing yield appeal against duration risk in a higher-rate environment.